Individualized Dosage of Tacrolimus for Renal Transplantation Patients Based on Pharmacometabonomics
Open Access
Abstract
The clinical pharmacodynamics of tacrolimus in renal transplant patients has significant interindividual variability. T lymphocytes were selected to study the pharmacodynamic response of tacrolimus, which was significantly correlated with renal function and the outcome of renal transplant patients. Ultra-performance liquid chromatography–quadrupole time-of-flight mass spectroscopy (UPLC/Q-TOF-MS) was performed to obtain the metabolic profiles of 109 renal transplant patients. A partial least squares (PLS) model was constructed to screen potential biomarkers that could predict the efficacy of tacrolimus. Multinomial logistic regression analysis established a bridge that could quantify the relationship between the efficacy of tacrolimus and biomarkers. The results showed a good correlation between endogenous molecules and the efficacy of tacrolimus. Metabolites such as serum creatinine, mesobilirubinogen, L-isoleucine, 5-methoxyindoleacetate, eicosapentaenoic acid, N2-succinoylarginine, tryptophyl-arginine, and butyric acid were indicated as candidate biomarkers. In addition, the key biomarkers could correctly predict the efficacy of tacrolimus with an accuracy of 82.5%. Finally, we explored the mechanism of individual variation by pathway analysis, which showed that amino acid metabolism was significantly related to the efficacy of tacrolimus. Moreover, orthogonal partial least squares discriminant analysis (OPLS-DA) showed that there was no difference in key metabolites among different pharmacodynamic groups at 1 month and 3 months after dose adjustment, suggesting that pharmacometabonomics is a useful tool to predict individual differences in pharmacodynamics and thus to facilitate individualized drug therapy.Keywords
Funding Information
- Zhejiang Provincial Natural Science Foundation (LYY22H310014)
This publication has 37 references indexed in Scilit:
- Tacrolimus Inhibits NF-κB Activation in Peripheral Human T CellsPLOS ONE, 2013
- Personalised medicine: not just in our genesBMJ, 2012
- Pharmaco‐metabolomics: An emerging “omics” tool for the personalization of anticancer treatments and identification of new valuable therapeutic targetsJournal of Cellular Physiology, 2011
- Rejection of the Kidney AllograftNew England Journal of Medicine, 2010
- Lymphocytes and ischemia-reperfusion injuryTransplantation Reviews, 2009
- Tryptophan and the immune responseImmunology & Cell Biology, 2003
- AN OPEN-LABEL, CONCENTRATION-RANGING TRIAL OF FK506 IN PRIMARY KIDNEY TRANSPLANTATIONTransplantation, 1996
- Identification of calcineurin as a key signalling enzyme in T-lymphocyte activationNature, 1992
- THE EFFECTS OF DIETARY SUPPLEMENTATION WITH FISH OIL ON RENAL FUNCTION IN CYCLOSPORINE-TREATED RENAL TRANSPLANT RECIPIENTSTransplantation, 1990
- Inhibition of prostaglandin biosynthesis by eicosapentaenoic acidProstaglandins and Medicine, 1979